194 related articles for article (PubMed ID: 33735585)
1. Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.
Guzman-Holst A; de Barros E; Rubio P; DeAntonio R; Cintra O; Abreu A
Hum Vaccin Immunother; 2022 Dec; 18(1):1879578. PubMed ID: 33735585
[TBL] [Abstract][Full Text] [Related]
2. Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program.
Moreira M; Cintra O; Harriague J; Hausdorff WP; Hoet B
Vaccine; 2016 May; 34(25):2766-78. PubMed ID: 27113162
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
Lagoubi Y; Sfar MT; Gomez JA
Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
[TBL] [Abstract][Full Text] [Related]
6. Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil.
Gomez JA; Lopes de Abreu AJ; Caceres DC; Nieto J; Ortega-Barria E
Pediatr Infect Dis J; 2019 Oct; 38(10):e260-e265. PubMed ID: 31568144
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L
J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273
[TBL] [Abstract][Full Text] [Related]
8. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
De Wals P; Black S; Borrow R; Pearce D
Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
[TBL] [Abstract][Full Text] [Related]
9. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
[TBL] [Abstract][Full Text] [Related]
11. Ten years of experience with the pneumococcal non-typeable
Lecrenier N; Marijam A; Olbrecht J; Soumahoro L; Nieto Guevara J; Mungall B
Expert Rev Vaccines; 2020 Mar; 19(3):247-265. PubMed ID: 32195602
[No Abstract] [Full Text] [Related]
12. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
[TBL] [Abstract][Full Text] [Related]
14. 10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.
Plosker GL
Paediatr Drugs; 2014 Oct; 16(5):425-44. PubMed ID: 25192686
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
Hammitt LL; Ojal J; Bashraheil M; Morpeth SC; Karani A; Habib A; Borys D; Goldblatt D; Scott JA
PLoS One; 2014; 9(1):e85459. PubMed ID: 24465570
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media.
Izurieta P; Scherbakov M; Nieto Guevara J; Vetter V; Soumahoro L
Hum Vaccin Immunother; 2022 Dec; 18(1):2013693. PubMed ID: 35020530
[TBL] [Abstract][Full Text] [Related]
18. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ
Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422
[TBL] [Abstract][Full Text] [Related]
19. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
Leach AJ; Wigger C; Hare K; Hampton V; Beissbarth J; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
BMC Pediatr; 2015 Oct; 15():162. PubMed ID: 26482232
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience.
Mrkvan T; Pelton SI; Ruiz-Guiñazú J; Palmu AA; Borys D
Expert Rev Vaccines; 2018 Sep; 17(9):797-818. PubMed ID: 30185083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
